• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and experimental allergy : >Molecular characterization of a human immunoglobulin G4 antibody specific for the major birch pollen allergen, Bet v 1.
【24h】

Molecular characterization of a human immunoglobulin G4 antibody specific for the major birch pollen allergen, Bet v 1.

机译：对主要桦树花粉变应原Bet v 1.具有特异性的人免疫球蛋白G4抗体的分子表征。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Allergen-specific IgG4 antibodies induced by specific immunotherapy are thought to represent a protective immune response. Objective Our aim was the molecular characterization of a human IgG4 antibody (BAB5) specific for the major birch pollen allergen Bet v 1 that was derived from an immunotherapy-treated patient. METHODS: The cDNA coding for BAB5 was obtained by reverse transcriptase-PCR from the BAB5-producing cell line, compared with the germ line sequences and was expressed as a soluble antibody fragment in Escherichia coli. The epitope specificity and cross-reactivity of BAB5 were investigated with recombinant and synthetic Bet v 1 fragments and Bet v 1 homologous allergens from pollen. The ability of BAB5 to block allergic patients IgE was determined by competition experiments and sandwich ELISA. RESULTS: BAB5 is an affinity-matured Bet v 1-specific IgG4 antibody that reacts exclusively with Bet v 1 but not with Bet v 1-related allergens. Unlike an earlier-described monoclonal IgG1-blocking antibody, BAB1, which had been isolated from the same patient, BAB5 did not block allergic patients' IgE reactivity to Bet v 1. CONCLUSION: Our study demonstrates that not all allergen-specific IgG antibodies inhibit IgE recognition of allergens and can contribute to the success of immunotherapy. The epitope specificity and affinity of IgG antibodies but not their isotype are decisive for their protective activity.
机译：背景：通过特异性免疫疗法诱导的过敏原特异性IgG4抗体被认为代表了保护性免疫反应。目的我们的目标是对主要的桦树花粉变应原Bet v 1具有特异性的人IgG4抗体（BAB5）的分子特征，该抗体衍生自经过免疫治疗的患者。方法：通过逆转录酶-PCR从产BAB5细胞系中获得编码BAB5的cDNA，并将其与种系序列进行比较，并在大肠杆菌中表达为可溶性抗体片段。用重组和合成的Bet v 1片段和来自花粉的Bet v 1同源变应原研究了BAB5的表位特异性和交叉反应性。通过竞争实验和夹心ELISA确定BAB5阻断过敏患者IgE的能力。结果：BAB5是亲和力成熟的Bet v 1特异性IgG4抗体，仅与Bet v 1反应，但不与Bet v 1相关的过敏原反应。与先前从同一患者中分离出的先前描述的单克隆IgG1阻断抗体不同，BAB5并未阻断变应性患者对Bet v 1的IgE反应性。结论：我们的研究表明，并非所有变应原特异性IgG抗体都能抑制IgE对过敏原的识别，可以促进免疫疗法的成功。 IgG抗体的表位特异性和亲和力，而不是其同种型，对其保护活性起决定性作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号